PBN FASTEST GROWING COMPANIES 2020 $5M – $25M
5. EpiVax Inc.
CEO (or equivalent): Dr. Anne De Groot, CEO and chief scientific officer
2019 Revenue: $6.8 million
2017 Revenue: $4.7 million
Revenue growth: 44.7%
ONE COMPANY THAT BEGAN in a Brown University lab is finding that work in the microscopic world of immunology can help profits go viral.
Start 2025 Strong: Prioritize Your Health with Screenings and Healthy Habits
As we step into 2025, there’s no better time to make a commitment to your…
Learn More
Providence-based EpiVax Inc.’s earnings grew to $6.8 million in 2019, a 44.7% boost of $2.1 million over three years.
The 20-year-old company uses cutting-edge tools founder Dr. Anne De Groot developed while at Brown to screen and analyze pharmaceuticals for unwanted responses from the immune system.
“That’s where we excel – is helping companies avoid a problem with their drugs,” said De Groot, EpiVax’s CEO and chief scientific officer.
This spring, EpiVax added a COVID-19 cure to its growing list of vaccines and immunotherapies under research and development for infectious diseases, autoimmunity and cancer.
EpiVax has also been licensing its novel immune-modulating Tregitope technology to pharmaceutical companies for their research and development.
“It’s a culture largely revolving around curiosity,” said Cliff Grimm, chief financial officer and business officer. “That’s what gets us to where we are.”
